.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,475,813

« Back to Dashboard

Details for Patent: 8,475,813

Title:Methods of treatment using a gastric retained gabapentin dosage
Abstract: A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.
Inventor(s): Berner; Bret (Half Moon Bay, CA), Hou; Sui Yuen Eddie (Foster City, CA)
Assignee: Depomed, Inc. (Newark, CA)
Filing Date:Nov 21, 2011
Application Number:13/301,570
Claims:1. An oral dosage form, comprising an osmotic device comprising a core comprising gabapentin, and a semipermeable membrane surrounding the core, wherein the semipermeable membrane comprises a plasticizer, is permeable to a fluid in an environment of use and is substantially impermeable to unsolubilized gabapentin, wherein the oral dosage form as formulated is of sufficient size to promote retention in the stomach of a subject in the fed mode for a period of at least about 5 hours, wherein the dosage form is a tablet comprising about 100 mg to about 4800 mg gabapentin, wherein the gabapentin is released into the upper gastrointestinal tract over a period of about 5-12 hours at a rate sufficient to achieve a lower maximum plasma concentration (C.sub.max) compared to an equal dose of gabapentin provided by an immediate release dosage form.

2. The dosage form of claim 1, wherein the dosage form provides bioavailability of gabapentin at a level greater than or equal to 80 % of that provided by an equal dose of gabapentin released by the immediate release dosage form as measured by the plasma AUC.sub.inf.

3. The dosage form of claim 1, wherein the osmotic device comprises an elementary pump.

4. The dosage form of claim 1, wherein the dosage form comprises about 300 mg or about 600 mg gabapentin.

5. The dosage form of claim 1, further comprising a second therapeutic agent selected from the group consisting of a hydantoin, an iminostilbene, a valproate, a phenyltriazine, a barbiturate, a deoxybarbiturate, a benzodiazepine, a carbamate, an anticonvulsant other than gabapentin, a tricyclic antidepressant, levadopa, carbidopa, an opioid, lithium, carbamazepine, valproate, trifluoperazine, clonazepam, risperidone, lorazepam, venlafaxine, clozapine, olanzapine, a benzodiazepine, a neuroleptic, a serotonin reuptake inhibitor, buproprion, nefadone, venlaxatine, nefadone, diazepam, oxazepam, a dopaminergic agent, clonazepam, a triptan and ergotamine.

6. The dosage form of claim 1, wherein the osmotic device comprises a push-pull osmotic device comprising a first osmotic composition and a second osmotic composition housed in a compartment of the push-pull osmotic device.

7. The dosage form of claim 6, wherein the dosage form provides for bioavailability of gabapentin at a level greater than or equal to 80 % of that provided by an equal dose of gabapentin released by the immediate release dosage form as measured by the plasma AUC.sub.inf.

8. The dosage form of claim 6, wherein the dosage form comprises about 300 mg or about 600 mg gabapentin.

9. The dosage form of claim 6, further comprising a second therapeutic agent selected from the group consisting of a hydantoin, an iminostilbene, a valproate, a phenyltriazine, a barbiturate, a deoxybarbiturate, a benzodiazepine, a carbamate, an anticonvulsant other than gabapentin, a tricyclic antidepressant, levadopa, carbidopa, an opioid, lithium, carbamazepine, valproate, trifluoperazine, clonazepam, risperidone, lorazepam, venlafaxine, clozapine, olanzapine, a benzodiazepine, a neuroleptic, a serotonin reuptake inhibitor, buproprion, nefadone, venlaxatine, nefadone, diazepam, oxazepam, a dopaminergic agent, clonazepam, a triptan and ergotamine.

10. The dosage form of claim 1, wherein the osmotic device comprises a macroporous membrane.

11. The dosage form of claim 10, wherein the dosage form provides for bioavailability of gabapentin at a level greater than or equal to 80 % of that provided by an equal dose of gabapentin released by the immediate release dosage form as measured by the plasma AUC.sub.inf.

12. The dosage form of claim 10, wherein the dosage form comprises about 300 mg or about 600 mg gabapentin.

13. The dosage form of claim 10, further comprising a second therapeutic agent selected from the group consisting of a hydantoin, an iminostilbene, a valproate, a phenyltriazine, a barbiturate, a deoxybarbiturate, a benzodiazepine, a carbamate, an anticonvulsant other than gabapentin, a tricyclic antidepressant, levadopa, carbidopa, an opioid, lithium, carbamazepine, valproate, trifluoperazine, clonazepam, risperidone, lorazepam, venlafaxine, clozapine, olanzapine, a benzodiazepine, a neuroleptic, a serotonin reuptake inhibitor, buproprion, nefadone, venlaxatine, nefadone, diazepam, oxazepam, a dopaminergic agent, clonazepam, a triptan and ergotamine.

14. The dosage form of claim 1, wherein the plasticizer is selected from acetylated monoglycerides, dibutyl phthalate, diethyl phthalate, isopropyl phthalate, dimethyl phthalate, dactyl phthalate, dibutyl sebacate, dimethyl sebacate, esters, fatty acids, glycols, oils, glycerin, glycerol, glycerol monostearate, and triacetin.

15. The dosage form of claim 14, wherein the plasticizer is selected from esters and fatty acids.

16. The dosage form of claim 15, wherein the ester is selected from the group consisting of acetyl triethyl citrate, acetyl tributyl citrate, citrate ester, dibutyl sebacate, tetraethyl acetate, and triethyl citrate.

17. The dosage form of claim 15, wherein the fatty acid is a stearic acid.

18. The dosage form of claim 1, wherein the subject is a human.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc